Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early entrant to the field of machine learning for cardiology-focused clinical solutions. By leveraging large stores of deidentified data that span full patient journeys from physician notes to medications and imaging files, Anumana develops cardiac AI-based solutions that can glean pertinent disease information from electrocardiogram (ECG)waveforms. The company’s first FDA-cleared cardiac ECG-AI algorithm detects low ejection fraction (LEF), and two additional algorithms for pulmonary hypertension and cardiac amyloidosis are under review.
Anumana Makes Educated Inferences in Heart Failure
Related Articles
Tackling Imbalanced Regression in Clinical AI with KDE-weighted Deep Models
Clinical AI systems often include automated analysis of medical time series, such as electrocardiogram (ECG), to serve as valuable diagnostic decision support tools. While many cardiovascular diseases are traditionally measured…June 15, 2025
Anumana’s AI-Driven Low Ejection Fraction ECG-AI Technology Recognized in CMS 2025 OPPS Final Rule, Expanding Access to Advanced Cardiovascular Care
Company’s ECG-AI algorithm enables earlier heart failure detectionNovember 05, 2024
Trial demonstrates early AI-guided detection of heart disease in routine practice
EurekAlert: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early…April 18, 2021
Novartis links up with Mayo Clinic spinout Anumana to develop ECG-reading AI
FIERCE Biotech: Heart disease remains the leading cause of death around the world, but a flood of tech developers are hoping that artificial intelligence software might be the key to…July 13, 2022